INNV - Innovus Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0498
-0.0003 (-0.50%)
As of 12:38PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.0500
Open0.0500
Bid0.00000 x 0
Ask0.00000 x 0
Day's Range0.0486 - 0.0509
52 Week Range0.0440 - 0.1900
Volume223,302
Avg. Volume656,498
Market Cap12.181M
Beta (3Y Monthly)2.10
PE Ratio (TTM)N/A
EPS (TTM)-0.03900
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.34
Trade prices are not sourced from all markets
  • Business Wireyesterday

    Innovus Pharma Announces Regulatory Filings by its International Distribution Partner, Lavasta Pharma, for ProstaGorx® in Certain Gulf Countries

    Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today the submission of regulatory filings by its international distribution partner, Lavasta Pharma FZ-LLC, a company based in Dubai (“Lavasta”) for the commercialization of ProstaGorx® in the United Arab Emirates and Kuwait. Lavasta also has rights to this product in the Kingdom of Saudi Arabia, Algeria, Egypt, Lebanon, Jordan, Morocco, Tunisia, Bahrain, Oman, Qatar and Turkey, among other countries and is currently expected to continue to file for approval in the rest of its territory during this year.

  • Business Wire21 days ago

    Innovus Pharma’s Product FlutiCare® Ranks #2 Behind Flonase® in Amazon®’s Fluticasone Propionate and Allergy Nasal Spray Categories

    Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that its FlutiCare® OTC product for the relief of seasonal allergies is currently ranked #2 behind Flonase® in Amazon®’s Fluticasone Propionate and Allergy Nasal Spray categories. In addition, FlutiCare® is currently ranked #6 in Amazon’s Best Moisturizing Nasal Sprays category, #11 in the Best Allergy Medicine category and #41 in the Sinus Medicine category.

  • Business Wire22 days ago

    Innovus Pharma Announces the Approval and Launch of its OTC Hemorrhoid Xyralid® Suppositories in Canada

    Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the launch of its Xyralid® Suppositories, for the reduction of swelling or inflammation of hemorrhoidal tissues and provides pain relief from burning, itching and discomfort. Xyralid® Suppositories received a Product License Application (“PLA”) in Canada and the product is available as an over-the-counter (“OTC”) or behind the counter drug and will not require a prescription.

  • Business Wire2 months ago

    Innovus Pharmaceuticals Announces $3.17 Million Private Placement

    Innovus Pharmaceuticals, Inc. , an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it has entered into a definitive agreement with a healthcare-dedicated institutional investor for the sale of 45,306,347 shares of common ...

  • Business Wire2 months ago

    Innovus Pharma Announces All Cash Acquisition of All of the Assets of SupplementHunt.com, an E-Commerce Store with its Proprietary Sales Platform and Marketing Technology

    Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the acquisition for cash of all of the assets of SupplementHunt.com, an E-Commerce storefront with proprietary sales platform and marketing technology.

  • Business Wire2 months ago

    Innovus Pharma Announces Initiation of a Clinical Study to Evaluate the Tolerance and the Effect of Musclin™ on Muscle Health in Adults in the United States

    Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the enrollment of the first participant in the clinical study to evaluate the effect and tolerance of Musclin™ dietary supplement. The study is being conducted at a single site in the United States and is expected to enroll up to 20 healthy subjects.

  • ACCESSWIRE3 months ago

    SeeThruEquity Issues Update on Innovus Pharmaceuticals with Target Price of $0.80

    NEW YORK, NY / ACCESSWIRE / November 28, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on Innovus Pharmaceuticals, Inc. (INNV) with a Target Price of $0.80. Innovus Pharmaceuticals, Inc. (OTCQB: INNV, "Innovus") is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing, and development of over-the-counter (OTC) medicine and consumer care products to improve men's and women's health, respiratory disease and vitality. Led by CEO Dr. Bassam Damaj, Innovus is based in San Diego, CA and has demonstrated robust growth in its product offerings and annual revenues since we initiated coverage on the company in September 2014.

  • Zacks Small Cap Research3 months ago

    INNV: Innovus Pharmaceutical – Taking actionable steps to profitability

    There was a lot of good news in Innovus’ (INNV) third quarter report – higher subscription sales, strong growth in Canada and a slight decrease in absolute marketing spend. • Management’s comments were more focused than on the previous call and emphasized steps the INNV is taking to move to positive operating cash flow and, ultimately GAAP profitability. • Much of INNV’s path to profitability relies on increasing its subscription persistency.

  • Business Wire3 months ago

    Innovus Pharmaceuticals Acquires Worldwide Rights to Four Products from Boston Topicals, LLC

    Innovus Pharmaceuticals, Inc., (“Innovus Pharma”) (INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter and consumer care products to improve men’s and women's health and respiratory diseases, announced today that the Company has acquired four branded topical products from Boston Topicals, LLC (“Boston Topicals”), expanding its retail and e-commerce presence in the Company’s current highest revenue grossing category.

  • Business Wire3 months ago

    Innovus Pharma Reports Another New Quarterly Revenue Record of Approximately $7.4 Million for the Third Quarter 2018 and $19.2 Million for the First Nine Months of 2018

    The Company is in its Fifth Consecutive Quarter of Net Revenue Growth and Working Diligently Towards Exiting the Fourth Quarter 2018 Profitable

  • Business Wire3 months ago

    Innovus Pharmaceuticals to Release Its Third Quarter 2018 Financial Results on Wednesday, November 14, 2018

    Innovus Pharmaceuticals, Inc., , today announced that the Company will release its September 30, 2018 third quarter financial results on Wednesday, November 14, 2018, after the close of the U.S.

  • Zacks Small Cap Research4 months ago

    INNV: The Importance of Consistent Marketing Campaigns

    Innovus Pharamceutical (INNV) announced preliminary 3Q18 revenues of $7.0 - $7.1 million, up over 200% from $2.2 million in the year earlier period, but down sequentially from $7.3 million posted in 2Q18. In our initiation report (October 2, 2018), we noted that the supplements business differs from traditional pharmaceutical business. The supplements market relies more on customer interest than disease incidence.

  • Business Wire4 months ago

    Innovus Pharmaceuticals Reports Preliminary Q3 2018 Sales Revenue of $7.0 million to $7.1 million

    Innovus Pharmaceuticals, Inc., (“Innovus Pharma”) (INNV), today announced preliminary third quarter 2018 net revenue is estimated to be between $7.0 million to $7.1 million or an approximate 215-219% increase from the third quarter of 2017. Innovus Pharma's third quarter 2018 anticipated revenue results are preliminary and based on the most current information available and are subject to completion of the condensed consolidated financial statements for the third quarter of 2018, which are to be filed with the SEC no later than November 14, 2018. “We are excited that the exceptional growth in our sales channels, additional markets and product pipeline which we saw in Q2 2018 is continuing on a fairly even path in Q3 2018 with our estimated third quarter net revenue of between $7.0 million to $7.1 million.

  • ACCESSWIRE4 months ago

    SeeThruEquity Issues Update on Innovus Pharmaceuticals and Raises Target Price to $0.80

    NEW YORK, NY / ACCESSWIRE / October 25, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on Innovus Pharmaceuticals, Inc. (INNV) with a Target Price of $0.80. Innovus Pharmaceuticals, Inc. (OTCQB: INNV, "Innovus") is a fast-growing commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter (OTC) medicine and consumer care products to improve men and women's health, respiratory disease and vitality.

  • Business Wire4 months ago

    Innovus Pharma Receives Approval for Medicare Reimbursement for its GlucoGorx™ Blood Glucose Monitoring System and GlucoGorx™ Blood Glucose Test Strip Products

    Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, announced today that its GlucoGorx™ Blood Glucose Monitoring System and GlucoGorx™ Blood Glucose Test Strip products have become eligible for Medicare reimbursement. Specifically, the two products have been approved as Healthcare Common Procedure Coding System (“HCPCS”) numbers E0607 and A4253 products respectively after review by the Pricing, Data Analysis, and Coding Contractor (“PDAC”) for the U.S. Centers for Medicare and Medicaid Services (“CMS”).

  • Business Wire4 months ago

    Innovus Pharma Announces Planned Expansion into CBD Oil-Based Products Market

    Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it plans to expand its product line into the hemp-derived CBD (“Cannabinoid”) oil-based products market beginning in the fourth quarter 2018 with the introduction of MZS Sleeping Aid™, a supplement in tincture form delivering a 3 mg dose of melatonin per serving that incorporates either 100 or 250 mg of hemp-derived CBD oil. Innovus is also interested in expanding into other products using hemp-derived CBD oil that can benefit its customers in both countries and in other markets throughout the world.

  • Business Wire4 months ago

    Innovus Pharma Receives Approval from Amazon® to Expand its Amazon® Stores to Japan

    Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the approval from Amazon® for the expansion of its Amazon® stores to Japan. The additional store will increase the Company’s worldwide Amazon® store presence to its first country in Asia and is in addition to the Company’s Amazon® stores in the United States, Canada, Mexico and its new stores opening in the United Kingdom, France, Germany, Spain and Italy which it expects to launch in Q1 2019 or before.

  • Zacks Small Cap Research5 months ago

    INNV: Targeting high-demand consumer health needs with innovative products

    Innovus Pharmaceutical (INNV) commercializes and markets OTC and consumer health products. In the past year, the Company has introduced seven new products. Innovus has a strong pipeline and a very active direct marketing effort.

  • Business Wire6 months ago

    Innovus Pharma to Present at H.C. Wainwright 20th Annual Global Investment Conference

    Innovus Pharmaceuticals, Inc. , an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced that Dr.

  • ACCESSWIRE6 months ago

    SeeThruEquity Issues Update on Innovus Pharmaceuticals (INNV) and Raises Target Price to $0.75

    NEW YORK, NY / ACCESSWIRE / August 21, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on Innovus Pharmaceuticals, Inc. (INNV) and has raised its target price to $0.75. Innovus Pharmaceuticals, Inc. (OTCQB: INNV, "Innovus") is a fast-growing commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter (OTC) medicine and consumer care products to improve men and women's health, respiratory disease and vitality. Led by CEO Dr. Bassam Damaj, Innovus is based in San Diego, CA and has demonstrated robust growth in its product offerings and annual revenues since we initiated coverage on the company in September 2014.

  • Business Wire6 months ago

    Innovus Pharma Reports New Quarterly Revenue Record of $7.3 million for the Second Quarter 2018 and Expands to Canadian Market

    Beyond Human™ Sales & Marketing Strategy Results in 258.7% Net Revenue Growth Compared to Same Period in 2017

  • Business Wire6 months ago

    Innovus Pharma Signs Purchase Agreement with “Showcase – The Home of the Hottest Trends” to Sell the Company’s Apeaz® Cream for the Relief of Arthritis Pain in Its 110 “Showcase” Retail Stores in the United States and Canada

    Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it has entered into a purchase agreement with the nationwide retail store chain Showcase, a Canadian company for its drug Apeaz®, for arthritis pain relief. Apeaz® will be available in Showcase’s 110 stores across the United States and Canada and on its www.ShopAtShowcase.com portal starting mid-August, 2018.

  • Business Wire7 months ago

    Innovus Pharma Announces Three Regulatory Filings with Health Canada for Its Products: Xyralid® Suppositories, Beyond Human® Testosterone and RecalMax™

    Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the filing by it for regulatory approval in Canada for its (1) Xyralid® Suppositories drug for the relief of hemorrhoidal swelling, (2) Beyond Human® Testosterone to promote and maintain testosterone levels in men and (3) RecalMax™ for cognitive health and mental sharpness. The regulatory approval process for the three products may take anywhere up to 210 days for approval depending on the application.

  • Business Wire7 months ago

    Innovus Pharmaceuticals to Release Its Second Quarter 2018 Financial Results on Tuesday, August 14, 2018

    Innovus Pharmaceuticals, Inc. today announced that the Company will release its June 30, 2018 second quarter financial results on Tuesday, August 14, 2018, after the close of the U.S.

  • Business Wire7 months ago

    Innovus Pharma Signs Purchase Agreement with CVS Pharmacy, Inc. to Sell Its Product Androferti® to Increase Sperm Quality in Their Newly Established In-Store Men’s Clinic

    Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced that it has entered into a pilot program with the nationwide pharmaceutical chain CVS Pharmacy, Inc. (“CVS”), which is a subsidiary of CVS Health Corp (CVS), to sell the Company’s product Androferti®, to increase sperm quality. If successful, the CVS pilot program could lead to the national pharmacy stocking and selling Androferti® on a scalable level nationwide and could expand to add additional Innovus Pharma products.